MR

Michael Rome

Managing Director & Head of Therapeutics Investing at Foresite Capital

Los Angeles Metropolitan Area

VC
Investor

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Project Management
Presentation Development
DCF Valuation
Equity Valuation
Business Valuation
Intellectual Property Valuation
Financial Modeling
Business Modeling
Biotechnology
Private Equity
Venture Capital

Education

Investments

Alumis

Series A

Total Funding: $330M

Remix Therapeutics

Series A

Total Funding: $210M

CG Oncology

Series F

Total Funding: $110M

XinThera

Series B

Total Funding: $50M

Theseus Pharmaceuticals

Series B

Total Funding: $100M

Kinnate Biopharma

Series A

Total Funding: $200M

Nurix Therapeutics

Private Equity

Total Funding: $150M

Work Experience

Foresite Capital

2016

  • Managing Director

    2016

RayThera

2023

  • Board Member

    2023

CG Oncology

2023

  • Board Observer

    2023

Avenzo Therapeutics

2022

  • Board Member

    2022

Kinnate Biopharma Inc.

2018

  • Board Member

    2018

Alumis

2021

  • Board Member and Observer

    2021

Remix Therapeutics

2020

  • Board Member

    2020

XinThera Inc.

2021 - 2023

  • Board Member

    2021 - 2023

Affinivax Inc.

2021 - 2022

  • Board Observer

    2021 - 2022

Turning Point Therapeutics

2018 - 2019

  • Board Observer

    2018 - 2019

    Co-led series D financing